VTGN fundamentals
An in-depth look to VistaGen Therapeutics, Inc. operating, investing, and financing activities
VTGN free cash flow for Q3 23 is -4.57 M USD. For 2022, VTGN free cash flow was -49.93 M USD and operating cash flow was -49.72 M USD.
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: USD
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
TTM